A startup founded by former BioMarin executives closed an $82 million financing to acquire and develop rare‑disease programs that need new homes or fresh development strategies. The Bay Area firm said it will apply the team’s prior experience in rare disease development and commercialization to accelerate assets toward approval. The fundraise supports early asset acquisitions, preclinical optimization, and the formation of development partnerships. Management emphasized lessons from prior successes at BioMarin in scaling clinical, manufacturing, and market access pathways for orphan drugs. The move reflects a recurring post‑big‑pharma pattern: experienced operators recycling expertise and capital into asset‑centric companies focused on value creation in small markets. Source: fundraising announcement and founder commentary included in the original article.